We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The approval is the first for aspirin plus Brilinta in patients who have a high cardiovascular risk without a history of heart attack or stroke. Read More
The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended eight new drugs for approval at its May meeting, including Johnson and Johnson’s Ebola vaccine. Read More
The approval of the twice-daily doses was based on a reduction in serum ferritin levels, as there were no controlled trials demonstrating a direct treatment benefit. Read More